Metanoia Press · In preparation · Synthetic
MDMA is the outlier of the classic set. It is not really a "psychedelic" in the same sense — it doesn't primarily mimic serotonin at the 5-HT2A receptor the way the others do — and its signature is emotional warmth and openness rather than visions. It has also been the front-runner of the modern therapy movement, and its journey through regulation has taught the whole field hard lessons about evidence and expectation. Our forthcoming book covers it for completeness, with the same honesty about limits as about promise.
What the Book Will Cover
Why MDMA is an "empathogen," releasing serotonin rather than mimicking it — a genuinely different mechanism from the tryptamines.
Its central role in the PTSD research that brought psychedelic therapy into the mainstream conversation.
Why supporters and critics agree on one thing: the setting and the therapeutic frame do much of the work.
Neurotoxicity questions, the regulatory setbacks, and what the field learned from them.
MDMA works mainly by causing a large release of serotonin (along with dopamine and norepinephrine), rather than by directly activating the 5-HT2A receptor the way psilocybin and LSD do — which is why it produces closeness, trust, and reduced fear rather than classic visionary effects. That emotional profile is what made it the centerpiece of trauma-focused therapy research, where it is used to help people revisit difficult memories with less overwhelm.
Its story is also a lesson in humility. The regulatory path for MDMA-assisted therapy has had significant setbacks, prompting hard questions about trial design, expectation effects, and how much of the benefit comes from the therapy versus the molecule. We treat that honestly: real promise, real unresolved questions, and a reminder that enthusiasm is not evidence.
Reliability: mechanism is well established (strong); therapeutic evidence is substantial but contested, with notable regulatory setbacks. Full sources will accompany the finished book.